Stockscreener 앱 받기
2.40
6.98%
-0.18
시간 외 거래:
2.42
0.02
+0.83%
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price Target - Yahoo Finance
Phathom Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations - Yahoo
H.C. Wainwright cuts Phathom Pharma stock target to $20, keeps Buy rating - Investing.com Canada
Phathom Pharmaceuticals (PHAT) Price Target Lowered by Goldman Sachs | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Target Price Lowered by Guggenheim | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Tar - GuruFocus
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenhei - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript - Insider Monkey
PHAT Faces Price Target Cut Amidst Restructuring Efforts | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Phathom Pharmaceuticals Eyes Profitability Amid Growth - TipRanks
Phathom Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Phathom Pharmaceuticals Grants 186,508 Shares Package to New Sales Chief in Strategic Hire - Stock Titan
Phathom (PHAT) Implements Strategic Shift for Long-Term Growth | - GuruFocus
Phathom Pharmaceuticals Q1 2025 Earnings: EPS Matches Estimates at -$1.18, Revenue Falls Short at $28.5 Million - GuruFocus
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News
Phathom Pharmaceuticals stock hits 52-week low at $3.8 By Investing.com - Investing.com India
Phathom Pharmaceuticals to Report First Quarter 2025 Financial R - GuruFocus
Phathom Pharmaceuticals stock hits 52-week low at $3.8 - Investing.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Res - GuruFocus
Phathom Pharmaceuticals Q1 2025 Financial Results - TradingView
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BlackRock, Inc. Reduces Stake in Phathom Pharmaceuticals Inc. - GuruFocus
Phathom Pharmaceuticals Inc [PHAT] CFO and CBO makes an insider sale of 3,678 shares worth $16740.0. - knoxdaily.com
Uncovering the Potential of Phathom Pharmaceuticals Inc (PHAT) Stock - investchronicle.com
Upward Trajectory: Phathom Pharmaceuticals Inc (PHAT) Posts a Slidee, Closing at 4.11 - DWinneX
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting - GlobeNewswire
Groundbreaking GERD Treatment VOQUEZNA: First Real-World Data Release Coming at DDW 2025 - Stock Titan
Phathom Pharmaceuticals (PHAT) to Release Earnings on Thursday - Defense World
Phathom Pharmaceuticals Inc [PHAT] Shares Fall Approximately -55.18% Over the Year - knoxdaily.com
Was Phathom Pharmaceuticals Inc (PHAT)’s session last reading good? - uspostnews.com
Geode Capital Management LLC Acquires 155,577 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
SNL’s Kenan Thompson brings comedy chops to Phathom’s Voquezna campaign - Medical Marketing and Media
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 - The Manila Times
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals to Host Live Webcast for Q1 2025 Financial Results and Business Update on May 1, 2025 - Nasdaq
Phathom Pharmaceuticals To Report First Quarter 2025 Financial Results And Provide Business Update On Thursday, May 1, 2025 - marketscreener.com
Phathom Pharmaceuticals to Report First Quarter 2025 - GlobeNewswire
Phathom Pharmaceuticals Q1 Earnings Preview: Key VOQUEZNA Sales Data and Growth Strategy Reveal - Stock Titan
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock - MSN
Shares In Phathom Pharmaceuticals Inc (PHAT) -51.97% Down, YTD - Marketing Sentinel
Phathom Pharmaceuticals (NASDAQ:PHAT) Given “Buy” Rating at Needham & Company LLC - Defense World
Phathom Pharmaceuticals Inc’s Market Journey: Closing Weak at 4.03, Down -4.62 - DWinneX
Alliancebernstein L.P. Has $370,000 Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
The Goldman Sachs Group Cuts Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $10.00 - Defense World
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge - simplywall.st
Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years ago - Yahoo Finance
Phathom Pharmaceuticals appoints Ted Schroeder to board By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals appoints new board member By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals appoints Ted Schroeder to board - Investing.com Australia
5.24%
자본화:
|
볼륨(24시간):